Article Information
History
- December 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Political Science, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel, Moshe.maor{at}mail.huji.ac.il
- 2The Federmann School of Public Policy, The Hebrew University of Jerusalem, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel raanan.s-k{at}mail.huji.ac.il
- 3Department of Communication and Journalism, The Hebrew University of Jerusalem, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel meitalbalmas{at}gmail.com
- ↵*Corresponding author; email: moshe.maor{at}mail.huji.ac.il
Posted December 07, 2021.
The Reputational Dividends of Collaborating with a Highly Reputable Agency: The Case of the FDA and Its Domestic Partner Agencies
